Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Sintilimab in Advanced ESCC
NCT04813406Phase 2Unknown
- Sponsor
- Henan Provincial People's Hospital
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of anlotinib, sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Provincial People's Hospital. Status: unknown.
02
Drugs
anlotinibsintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04813406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04813406.